7-OH Kratom Detox
OUR APPROACH TO 7-OH DETOX
For individuals who are appropriate for residential withdrawal management, Salterra provides an individualized and structured detox setting that may include:
Comprehensive screening and assessment
24/7 staff support
Ongoing observation throughout withdrawal
Provider-directed medication management when appropriate
Coordination with medical providers
Individualized treatment and recovery planning
Continued residential treatment when clinically appropriate
Discharge and continuing-care planning
There is currently no single standardized treatment protocol specifically for 7-OH withdrawal. Published case reports have described medications such as buprenorphine or methadone in some patients, but treatment decisions should be individualized and made by an appropriate medical provider.
CONTINUING TREATMENT AFTER DETOx
Detox is often the beginning of treatment rather than the end of the recovery process. Depending on individual needs, continuing care may include:
Residential treatment
Individual and group therapy
Relapse-prevention and recovery planning
Family or support-person involvement when appropriate
Referral to PHP, IOP, outpatient care, sober living, or other continuing services
LEARN MORE ABOUT 7-OH KRATOM
Learn more about concentrated 7-OH products, warning signs of dependence, overdose risks, withdrawal, and recent federal action in our latest blog article.
What Is 7-OH Kratom?
7-Hydroxymitragynine (7-OH or 7-HMG) is an opioid-active alkaloid that occurs naturally in trace amounts in the kratom plant. Federal health concerns have focused primarily on products containing added, enhanced, or concentrated levels of 7-OH, including tablets, gummies, drink mixes, shots, and similar products.
Concentrated 7-OH products can produce potent opioid-like effects and have been associated with dependence, withdrawal, and other serious adverse effects. The FDA distinguishes these products from traditional kratom leaf containing naturally occurring trace amounts of 7-OH.
RISKS & DEPENDENCE
Opioid Receptor Activity: 7-OH acts on mu-opioid receptors and can produce opioid-like effects.
Concentrated Products: Added or enhanced levels of 7-OH may expose users to substantially greater amounts than would naturally occur in kratom leaf.
Tolerance & Dependence: Repeated use may lead to tolerance, physical dependence, cravings, and withdrawal symptoms when use is reduced or stopped.
Product Variability: Strength, ingredients, and labeling can vary among concentrated 7-OH products, making effects difficult to predict.
7-OH WITHDRAWAL SYMPTOMS
Withdrawal from concentrated 7-OH can resemble opioid withdrawal, but symptoms and severity vary from person to person. Reported symptoms may include:
Restlessness and irritability
Anxiety
Body aches
Sweating or chills
Nausea, vomiting, or gastrointestinal distress
Difficulty sleeping
Fatigue
Cravings
The amount and frequency of 7-OH use, length of use, other substances involved, and individual health factors can all affect the withdrawal experience. The FDA has received reports of dependence and withdrawal symptoms associated with concentrated 7-OH products.
FAQs
-
7-OH (7-hydroxymitragynine) is a concentrated opioid-like alkaloid derived from kratom that is far more potent than the whole leaf. Unlike traditional kratom, 7-OH products often behave like synthetic opioids, increasing risk of dependence and overdose
-
Federal health authorities, including recent statements from Robert F. Kennedy Jr.’s administration, have raised alarms about the opioid-like potency, unregulated distribution, and rising misuse of concentrated 7-OH products—prompting moves toward Schedule I classification to curb emerging harms.
-
Signs include increased tolerance, cravings, secretive use, withdrawal-like irritability, sedation, mood swings, and difficulty functioning without the substance.
-
Yes. Because of its potency and inconsistent labeling, 7-OH can depress breathing, cause unconsciousness, and lead to fatal overdose—especially when combined with other depressants.
-
Withdrawal mirrors opioid withdrawal: muscle aches, nausea, vomiting, anxiety, insomnia, sweating, and intense cravings. Medically supervised detox significantly improves safety and outcomes.
-
Yes. MAT (e.g.,Suboxone®/buprenorphine) can be part of a clinically supervised detox to reduce cravings and ease withdrawal while clients stabilize mentally and physically.
-
Encourage a medical evaluation, avoid judgmental language, ensure they have naloxone available, and help them connect to a supervised detox program. Remove unregulated products from their environment if safe to do so.